Compositions and methods for targeted delivery to cells
US-2024390271-A1 · Nov 28, 2024 · US
HMGB1 variants and uses thereof
US10626153B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10626153-B2 |
| Application number | US-201314416128-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 26, 2013 |
| Priority date | Jul 26, 2012 |
| Publication date | Apr 21, 2020 |
| Grant date | Apr 21, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to HMGB1 variants that maintain HMGB1 wild type chemoattractant function while displaying abolished cytokine and/or chemokine stimulating properties. Such molecules are useful in therapy.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating injured skeletal muscle or fractured bone in a subject in need thereof, the method comprising administering to the subject an amount of a High Mobility Group Box 1 (HMGB1) variant effective to promote healing of injured skeletal muscle or fractured bone, wherein the variant HMGB1 consists of SEQ ID NO: 1, wherein cysteine residues at positions 23, 45, and 106 of SEQ ID NO: 1 are replaced by serine residues. 2. The method of claim 1 , wherein the HMGB1 variant is a cell chemoattractant that does not stimulate cytokine and/or chemokine production from a cell. 3. The method of claim 1 , wherein the HMGB1 variant will not induce TNF expression in macrophages. 4. The method of claim 1 , wherein the HMGB1 variant is administered to the subject systemically. 5. The method of claim 1 , wherein the HMGB1 variant is administered to the subject by local injection to the muscle or bone to be treated. 6. A method for limiting damage to muscle in a subject having muscle that has been injured, comprising administering to the subject an effective amount of a High Mobility Group Box 1 (HMGB1) variant, wherein the variant HMGB1 consists of SEQ ID NO: 1, wherein cysteine residues at positions 23, 45, and 106 of SEQ ID NO: 1 are replaced by serine residues. 7. The method of claim 6 , wherein the HMGB1 variant is administered to the subject by local injection to the muscle. 8. The method of claim 6 , wherein the HMGB1 variant is administered to the subject systemically. 9. The method of claim 6 , wherein the muscle is skeletal muscle.
Assignees
Inventors
Classifications
Enzyme inhibitors (protease inhibitors A61K38/55) · CPC title
- C07K14/47Primary
from mammals · CPC title
Drugs for disorders of the muscular or neuromuscular system · CPC title
Drugs for skeletal disorders · CPC title
from mammals · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10626153B2 cover?
- The present invention relates to HMGB1 variants that maintain HMGB1 wild type chemoattractant function while displaying abolished cytokine and/or chemokine stimulating properties. Such molecules are useful in therapy.
- Who is the assignee on this patent?
- Ospedale San Raffaele Srl, Univ Degli Studi Di Milano—Bicocca
- What technology area does this patent fall under?
- Primary CPC classification C07K14/47. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).